VolitionRx Achieves Finger-Prick Sepsis Test Milestone, Expanding Market Reach

Event summary

  • VolitionRx successfully detected nucleosomes in capillary blood from sepsis patients using a finger-prick lateral flow prototype.
  • The test could enable bedside, ER, or at-home sepsis detection, expanding beyond centralized lab testing.
  • Study results demonstrate feasibility for rapid, minimally invasive point-of-care testing in various settings.
  • VolitionRx aims to provide quantitative readouts for clinical decision-making on a low-cost platform.
  • Global sepsis cases estimated at 166 million, with 31.5% of total deaths in 2021 attributed to sepsis.

The big picture

VolitionRx's breakthrough in finger-prick sepsis testing positions it as a pioneer in capillary blood-based nucleosome diagnostics. This innovation addresses critical unmet diagnostic needs and expands the company's market potential beyond traditional hospital infrastructure. The global sepsis market represents a significant opportunity, particularly in regions with limited laboratory access. VolitionRx's ability to provide rapid, cost-effective testing could improve patient outcomes and drive widespread adoption.

What we're watching

Market Expansion
How VolitionRx's decentralized testing capability will impact its total addressable market, particularly in low-income countries.
Commercialization Pace
The speed at which VolitionRx can secure NGO partnerships and strategic collaborations to accelerate commercialization.
Regulatory Approvals
Whether the company can obtain necessary regulatory clearances for its finger-prick sepsis test.

Related topics

Biotechnology